Atıf İçin Kopyala
Bayar E., Cevik M., Caker S., Cagatay P., SÜSLEYİCİ B.
CURRENT DRUG SAFETY, cilt.16, sa.3, ss.252-258, 2021 (ESCI)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
16
Sayı:
3
-
Basım Tarihi:
2021
-
Doi Numarası:
10.2174/1574886315666210106141936
-
Dergi Adı:
CURRENT DRUG SAFETY
-
Derginin Tarandığı İndeksler:
Emerging Sources Citation Index (ESCI), Scopus, PASCAL, Biotechnology Research Abstracts, EMBASE, MEDLINE
-
Sayfa Sayıları:
ss.252-258
-
Anahtar Kelimeler:
AML-12 hepatocytes, 3T3-L1 adipocytes, clopidogrel, cell culture, DNA damage, DNA fragmentation, FATTY-ACID OXIDATION, IN-VIVO, INSULIN-RESISTANCE, CYTOCHROME-P450 3A, ADIPOSE-TISSUE, COMET ASSAY, ANTIPLATELET, TICLOPIDINE, CELLS, METABOLISM
-
Marmara Üniversitesi Adresli:
Evet
Özet
Background: Clopidogrel has been commonly prescribed as a selective P2Y(12) receptor antagonist to reduce heart attack and stroke risk. Nearly 10% of absorbed clopidogrel is metabolized to active forms by cytochrome P450 (CYP) enzymes in the liver and 90% to inactive clopidogrel carboxylate by esterases.